CAJ | 학술논문

脱-γ-羧基凝血酶原(DCP)是肝癌细胞产生的异常凝血酶原,其机制可能与癌细胞对维生素K利用障碍、依赖维生素K的γ谷氨酰羧化酶及辅酶活性降低,致内质网产生的凝血酶原N端10个谷氨酸残基羧化不全有关.DCP可以作为肝细胞癌诊断的标志物,还可能具有刺激癌细胞生长的作用.抑制肝癌细胞产生DCP,能达到治疗肝癌的目的 .维生素K及其衍生物被认为可能具有抑制肝癌细胞产生DCP的作用,其机制可能与促进肝癌细胞γ谷氨酰羧化酶活性有关.
탈-γ-최기응혈매원(DCP)시간암세포산생적이상응혈매원,기궤제가능여암세포대유생소K이용장애、의뢰유생소K적γ곡안선최화매급보매활성강저,치내질망산생적응혈매원N단10개곡안산잔기최화불전유관.DCP가이작위간세포암진단적표지물,환가능구유자격암세포생장적작용.억제간암세포산생DCP,능체도치료간암적목적 .유생소K급기연생물피인위가능구유억제간암세포산생DCP적작용,기궤제가능여촉진간암세포γ곡안선최화매활성유관.
Des-γ-carboxy prothrombin (DCP)is produced abnormally in hepatocellular carcinoma cells. Vitamin K utilizing deficiency and the decreasing activity of vitamin K-dependent γ-glutamyl carboxylate and coenzyme may involve in production of DCP. The enzymes in bepatocellular carcinoma cells are failed in carboxylating all the ten glutamic acid residues in amino- terminus of prothrombin precursor to Gla and make the difference between DCP and prothrombin. DCP is considered to be the marker for diagnosis of hepatocellular carcinoma. DCP might also be one of the growth-promoting factors to carcinoma cells. Therefore, inhibition of DCP in hepatocellular carcinoma cells is considered to be the therapeutic method of blocking hepatocellular car-cinoma growth. Vitamin K and its analogs are found to have the functions of inhibiting hepatocellular carcinoma cell producing DCP. The mechanism may relate to the increase of γ-glutamyl carboxylase activity.